![[HTML version]](/e/graphics/htmlborder.gif)
![[PDF version]](/e/graphics/pdfborder.gif)
![[CIF]](/e/graphics/cifborder.gif)
![[3d view]](/e/graphics/3dviewborder.gif)
![[Structure Factors]](/e/graphics/structurefactorsborder.gif)
![[CIF check Report]](/e/graphics/checkcifborder.gif)
![[Buy article online]](/logos/buy.gif)
![[Contents scheme]](bt6518contents.gif)
Acta Cryst. (2004). E60, o1862-o1864 [ doi:10.1107/S1600536804023529 ]
Abstract: The crystal structure of the title compound, C18H16ClN3O3, was determined because of its biological and pharmaceutical properties. In the molecule, the spiro junction links a planar oxindole ring and a pyrrolidine ring. The pyrrolodine ring is in an envelope conformation. The methyl, nitro and chlorophenyl groups are equatorial with respect to the pyrrolidine ring. A centrosymmetric dimer is formed via N-H
O intermolecular hydrogen bonds. C-H
O and C-H
Cl intermolecular hydrogen bonds stabilize the molecules in the crystal structure. A couple of weak C-H
intermolecular interactions are also observed.
Online 30 September 2004
Copyright © International Union of Crystallography
IUCr Webmaster